Hydreight Highlights U.S. Patent Allowance for Insu Therapeutics' Needle-Free Insulin and GLP-1 Delivery Technology

(TSXV:NURS) (OTCQB:HYDTF) (FSE:SO6) (CSE:VST) (OTC:VSQTF) Hydreight Technologies Inc. announced that Insu Therapeutics Inc., in which Hydreight holds a strategic investment, has received a Notice of Allowance from the United States Patent and Trademark Office for a patent application covering its buccal peptide-delivery technology. The patent application, U.S. Patent Application No. 18/513,373, is titled 'Mucoadhesive Pharmaceutical Dosage Form for Unidirectional Release of Peptide Therapeutic Particles.' Hydreight completed a C$300,000 investment in Insu and obtained U.S. distribution rights for peptide medicines incorporating Insu's buccal technology, as disclosed in its March 13, 2026 news release. Insu holds an exclusive, worldwide licence from the University of British Columbia to develop, market, commercialize, and sublicense the licensed technology globally. The allowed claims relate to the platform's mucoadhesive, layered dosage-form architecture and unidirectional release mechanism for insulin and GLP-1 therapeutics, including semaglutide, liraglutide, dulaglutide, exenatide, and multiple insulin analogues. InsuTab™ and BuccaGLP™ are Insu's investigational buccal insulin and semaglutide formulations, respectively, and both remain investigational and are not approved for commercial sale. Insu has completed laboratory, cell-culture, and rat studies at UBC as proof-of-concept work for its buccal insulin program. Hydreight's platform connects healthcare providers, pharmacies, and patients across all 50 U.S. states and supports a network of more than 3,000 nurses and more than 300 independent doctors and pharmacy relationships. Hydreight's VSDHOne platform, developed in partnership with Victory Square Technologies (CSE:VST, OTC:VSQTF, FSE:6F6), supports businesses delivering physician-supervised healthcare through virtual and direct-to-consumer channels. Insu's technology is designed to deliver peptide medicines through the lining of the mouth, providing a potential needle-free alternative to injections, and does not require fasting or restrictions on food and drink before or after dosing. The patent allowance strengthens Hydreight's strategic investment and potential future U.S. distribution opportunity, but any future introduction would require successful development, regulatory approvals, and appropriate product-specific prescribing, pharmacy, and operational arrangements. The scope of patent protection will be determined by the final issued claims. Insu's research was published in Pharmaceutics in September 2023 (15(9):2265). Shane Madden is the Chief Executive Officer and Director of Hydreight Technologies Inc. Dr. Anubhav Pratap-Singh is Board chair and Co-Founder of Insu Therapeutics. Insu holds related patent applications in the United States, Canada, Europe, and Japan.

Hydreight Provides Business Update on its Peptide Healthcare Platform Following Recent FDA Advisory Committee Recommendations

(TSXV: NURS) Hydreight Technologies Inc. provided an update on its peptide healthcare platform following the July 23–24, 2026 recommendations of the U.S. Food and Drug Administration's Pharmacy Compounding Advisory Committee (PCAC), which advised that six peptide-related bulk drug substances be considered for inclusion on the FDA's Section 503A Bulks List. The company currently supports multiple peptide-based treatment categories, including GLP-1 therapies, Sermorelin, and Ipamorelin, through its nationwide physician, pharmacy, and technology platform. Hydreight has sold more than 12,000 VSDHOne licenses, compared to approximately 3,000 at the end of 2025, and operates a network of over 300 licensed physicians and more than 3,000 licensed nurses across all 50 U.S. states. The company has made substantial investments in physician infrastructure, pharmacy relationships, clinical protocols, and technology supporting peptide-based care since 2019. Earlier in 2026, Hydreight announced a strategic investment in Insu Therapeutics Inc., a biotechnology company developing proprietary buccal drug delivery technology for peptide and biologic medicines. The company projects continued expansion of its physician, pharmacy, and technology infrastructure and anticipates further growth and scaling of its VSDHOne and other platform offerings. Hydreight's platform is designed to enable businesses to launch direct-to-consumer healthcare brands in a matter of days in all 50 states.

Hydreight Announces Refiling of Interim Financial Statements

(TSXV:NURS) Hydreight Technologies Inc. announced that it has refiled its condensed interim consolidated financial statements for the three months ended March 31, 2026 and 2025 on SEDAR+ to correct classification errors in segment financial information and disaggregation of revenue disclosures included in Note 16 – Operating Segments. The corrections relate to the classification of revenue between pharmacy sales within the Mobile Medical Services and Virtual Healthcare – Direct to Consumer segments. The company stated that these corrections do not impact total revenues, gross profit, net income, cash flows, balance sheet amounts, or any other previously reported financial results for the three months ended March 31, 2026 and 2025. There are no changes to the Company's reported financial results for the three months ended March 31, 2026 and 2025. Hydreight Technologies Inc. has hosted a network of over 3,000 nurses, over 300 doctors, and a pharmacy network through its doctor networks across all 50 states. The Hydreight platform includes a built-in, easy-to-use suite of fully integrated tools for accounting, documentation, sales, inventory, booking and managing patient data. The company is building one of the largest mobile clinic networks in the United States.

Hydreight Delivers Record First Quarter 2026 Revenue of $24.9 Million with 449% Revenue Growth, $3.3 Million in Adjusted EBITDA² and $32.0 Million in Working Capital

(TSXV: NURS) Hydreight Technologies Inc. reported record revenue of $24.9 million for Q1 2026, with Adjusted Revenue of $27.6 million and gross profit of $5.1 million. The Company generated net income of $2.6 million during the quarter, ending with $24.2 million in cash, $32.0 million in working capital, and $36.4 million in shareholders' equity. Revenue increased 449% year-over-year from $4.5 million in Q1 2025, while Adjusted EBITDA rose to $3.3 million from $0.2 million, a 1,412% increase. The Adjusted EBITDA margin expanded to 13.1% from 3.6% in the prior year. Over 12,000 VSDHOne licenses have been sold since launch, and operations now span all 50 U.S. states. The company projects it is 'firmly on track to deliver against our full-year 2026 guidance' and continues to invest in technology, infrastructure, and strategic partnerships.

Hydreight Reports Record Fiscal 2025 Results as VSDHOne Drives Rapid Growth and Platform Scale

Hydreight Technologies Inc. (TSXV: NURS, OTCQB: HYDTF) reported audited financial results for the year ended December 31, 2025, achieving profitability with net income of $1.69M and revenue of $35.4M, up 121% year-over-year. The company scaled to over 11,000 platform licenses and ended the year with a strong cash position of $15.65M. Adjusted Revenue reached $43.56M and Adjusted EBITDA was $2.54M, reflecting significant growth and improved operating leverage. Hydreight also completed a $15M financing in January 2026, bringing total accessible capital to over $30.7M. The company continues to expand its healthcare infrastructure platform across the United States, driven by the VSDHOne platform and strategic investments.